This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium CI
ABIOMED, Inc. Announces Termination of Todd A. Trapp as Chief Financial Officer CI
ABIOMED, Inc. Announces Management Changes CI
ABIOMED, Inc. Announces Termination of Michael R. Minogue as Chief Executive Officer CI
Johnson & Johnson Closes Acquisition of Abiomed MT
Abiomed, Inc.(NasdaqGS:ABMD) dropped from NASDAQ Composite Index CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Global 1200 CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Healthcare Equipment Select Industry Index CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equipment & Services (Industry Group) CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equipment & Supplies CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Composite 1500 CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equipment (Sub Ind) CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Growth CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Equal Weighted CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P TMI Index CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Global BMI Index CI
Johnson & Johnson completed the acquisition of Abiomed, Inc.. CI
Abiomed Says US FDA Approves Impella ECP Pivotal Heart Pump MT
Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP CI
Steel Dynamics to Join S&P 500; Super Micro Computer to be Added to S&P MidCap 400 MT
Johnson & Johnson Extends Abiomed Tender Offer to Dec. 21 MT
Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index CI
Chart Abiomed, Inc.
More charts
Abiomed, Inc. specializes in the development, manufacturing and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows: - sale of products (95.4%): heart pumps (Impella brand); - sale of services (4.6%): including preventive maintenance services. Net sales are distributed geographically as follows: the United States (81.2%), Europe (12.8%), Japan (5%) and other (1%).
More about the company
  1. Stock Market
  2. Equities
  3. ABMD Stock
  4. News Abiomed, Inc.
  5. Abiomed Posts Higher Fiscal Q2 Adjusted Earnings, Revenue